FindTrial
Sign In

[F-18]PBR06

DRUG6 trials

Sponsors

Brigham and Women's Hospital

Conditions

Alzheimer's DiseaseMSAMultiple SclerosisMultiple System AtrophyMultiple System Atrophy (MSA) With Orthostatic HypotensionMultiple System Atrophy, Cerebellar VariantMultiple System Atrophy, Parkinson Variant (Disorder)Relapsing Multiple Sclerosis

Early Phase 1

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
CompletedNCT04616456
Brigham and Women's HospitalMultiple System Atrophy, Multiple System Atrophy, Cerebellar Variant, Multiple System Atrophy (MSA) With Orthostatic Hypotension +1
Start: 2020-12-30End: 2022-01-30Updated: 2022-08-19

Phase 1

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RecruitingNCT02649985
Brigham and Women's HospitalAlzheimer's Disease, Multiple Sclerosis
Start: 2016-05-02End: 2027-12-31Target: 250Updated: 2026-01-28
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA
CompletedNCT03033680
Brigham and Women's HospitalMSA
Start: 2017-03-24End: 2021-01-15Updated: 2021-04-26
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
WithdrawnNCT03983252
Brigham and Women's HospitalMultiple Sclerosis
Start: 2021-12-31End: 2024-05-01Updated: 2025-10-17
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
NCT04144257
Brigham and Women's HospitalMultiple Sclerosis
Start: 2020-03-12End: 2021-09-30Target: 12Updated: 2021-07-28

Phase 3

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
CompletedNCT04510220
Brigham and Women's HospitalRelapsing Multiple Sclerosis
Start: 2020-09-21End: 2022-12-28Updated: 2026-01-27